ReviewAdvances in biochemical engineering/biotechnology2020
Advances in Vaccines.
Review in Advances in biochemical engineering/biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 30 citations in OpenAlex.
- VirusImmu: a novel ensemble machine learning approach for viral immunogenicity prediction.Briefings in functional genomics · 2025Article
- Silver Nanoparticles: Review of Antiviral Properties, Mechanism of Action and Applications.Microorganisms · 2023Review
- Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants.Frontiers in immunology · 2022Article
- Immune System Modulation by the Adjuvants Poly (I:C) and Montanide ISA 720.Frontiers in immunology · 2022Article
- Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.Vaccine · 2021Article
- Build a Sustainable Vaccines Industry with Synthetic Biology.Trends in biotechnology · 2021Review
- Fully Automated Screening of a Combinatorial Library to Avoid False Positives: Application to Tetanus Toxoid Ligand Identification.ACS omega · 2021Article
- mRNA vaccines manufacturing: Challenges and bottlenecks.Vaccine · 2021Review
- Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO.Scientific reports · 2021Article
- Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus.PLoS neglected tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines represent one of the most important advances in science and medicine, helping people around the world in preventing the spread of infectious diseases. However, there are still gaps in vaccination programs in many countries. Out of 11.2 million children born in EU region, more than 500,000 infants did not receive the complete three-dose series of diphtheria, pertussis, and tetanus vaccine before the first birthday. Data shows that there were more than 30,000 measles cases in the European region in recent years, and measles cases are rising in the USA. There are about 20 million children in the world still not getting adequate coverage of basic vaccines. Emerging infectious diseases such as malaria, Ebola virus disease, and Zika virus disease also threaten public health around the world. This chapter provides an overview of recent advances in vaccine development and technologies, manufacturing, characterization of various vaccines, challenges, and strategies in vaccine clinical development. It also provides an overview of recently approved major vaccines for human use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.